Literature DB >> 18037944

Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.

P Satwani1, N Cooper, K Rao, P Veys, P Amrolia.   

Abstract

Allogeneic hematopoietic SCT is well established as a potentially curative therapy for children and adults with both malignant and nonmalignant diseases. However, myeloablative SCT is associated with significant short- and long-term complications. The goals of a reduced intensity-conditioning (RIC) regimen are to prevent graft rejection and establish stable donor-derived hematopoiesis at a level sufficient for cure of the underlying disease and, in patients with hematologic malignancy, to provide a GVL effect, while decreasing the short- and long-term complications associated with myeloablative conditioning therapy. RIC regimens have enabled SCT to be performed in children with preexisting comorbidities that preclude conventional conditioning. RIC-SCT has been most extensively studied in patients with nonmalignant disorders and for some of these, including primary immunodeficiencies and hemophagocytic lymphohistiocytosis, sufficient data now exist to support its routine use even in patients without comorbidity. Less data exist on RIC-SCT for children with hematologic malignancies and at present this should be restricted to children who are not candidates for, or have relapsed after, myeloablative SCT. Here we review available data on the use of RIC-SCT in pediatric patients, highlighting important clinical lessons and areas that require further study.

Entities:  

Mesh:

Year:  2007        PMID: 18037944     DOI: 10.1038/sj.bmt.1705923

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  20 in total

1.  Molecular diagnosis of severe combined immunodeficiency--identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children.

Authors:  Pamela P W Lee; Koon-Wing Chan; Tong-Xin Chen; Li-Ping Jiang; Xiao-Chuan Wang; Hua-Song Zeng; Xiang-Yuan Chen; Woei-Kang Liew; Jing Chen; Kit-Man Chu; Lee-Lee Chan; Lynette Shek; Anselm C W Lee; Hsin-Hui Yu; Qiang Li; Chen-Guang Xu; Geraldine Sultan-Ugdoracion; Zarina Abdul Latiff; Amir Hamzah Abdul Latiff; Orathai Jirapongsananuruk; Marco H K Ho; Tsz-Leung Lee; Xi-Qiang Yang; Yu-Lung Lau
Journal:  J Clin Immunol       Date:  2010-12-24       Impact factor: 8.317

2.  Cardiac QTc interval characteristics before and after hematopoietic stem cell transplantation: an analysis of 995 consecutive patients at a single center.

Authors:  W P Miller; R Shanley; P Dorostkar
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

3.  Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC.

Authors:  M Strullu; C Thomas; M-C Le Deley; A Chevance; J Kanold; Y Bertrand; C Jubert; J-H Dalle; C Paillard; A Baruchel; L Lamant; G Michel; L Brugières
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

4.  Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.

Authors:  A Lawitschka; M Faraci; I Yaniv; P Veys; P Bader; J Wachowiak; G Socie; M D Aljurf; M Arat; J J Boelens; R Duarte; A Tichelli; C Peters
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

Review 5.  Bone marrow transplantation in Schimke immuno-osseous dysplasia.

Authors:  Alireza Baradaran-Heravi; Jonas Lange; Yumi Asakura; Pierre Cochat; Laura Massella; Cornelius F Boerkoel
Journal:  Am J Med Genet A       Date:  2013-08-15       Impact factor: 2.802

6.  Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.

Authors:  Rebecca A Marsh; Marepalli B Rao; Aharon Gefen; Denise Bellman; Parinda A Mehta; Pooja Khandelwal; Sharat Chandra; Sonata Jodele; Kasiani C Myers; Michael Grimley; Christopher Dandoy; Javier El-Bietar; Ashish R Kumar; Tom Leemhuis; Kejian Zhang; Jack J Bleesing; Michael B Jordan; Alexandra H Filipovich; Stella M Davies
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-10       Impact factor: 5.742

7.  Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.

Authors:  M Oda; K Isoyama; E Ito; M Inoue; M Tsuchida; H Kigasawa; K Kato; S Kato
Journal:  Int J Hematol       Date:  2009-03-18       Impact factor: 2.490

8.  Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.

Authors:  A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

9.  An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Authors:  Rebecca A Marsh; Mi-Ok Kim; Chunyan Liu; Denise Bellman; Laura Hart; Michael Grimley; Ashish Kumar; Sonata Jodele; Kasiani C Myers; Sharat Chandra; Tom Leemhuis; Parinda A Mehta; Jack J Bleesing; Stella M Davies; Michael B Jordan; Alexandra H Filipovich
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-10       Impact factor: 5.742

10.  Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes.

Authors:  Naima Al Mulla; Justine M Kahn; Zhezhen Jin; Mahvish Qureshi; Esra Karamehmet; Grace Yoon-Jeong Kim; Anya L Levinson; Monica Bhatia; James H Garvin; Diane George; Andrew L Kung; Prakash Satwani
Journal:  Biol Blood Marrow Transplant       Date:  2016-05-17       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.